Premium
Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease
Author(s) -
GambacortiPasserini Carlo,
Barni Rossella,
Marchesi Edoardo,
Verga Magda,
Rossi Francesca,
Rossi Fabio,
Pioltelli Pietro,
Pogliani Enrico,
Marco Corneo Gian
Publication year - 2001
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2001.02653.x
Subject(s) - chronic myelogenous leukemia , chronic myeloid leukaemia , medicine , philadelphia chromosome , blast crisis , abl , immunology , breakpoint cluster region , myeloid , myeloid leukemia , leukemia , disease , cancer research , biology , chromosomal translocation , genetics , receptor , tyrosine kinase , gene
STI571 (CGP57148B) is an inhibitor of BCR/ABL, the cause of chronic myeloid leukaemia (CML). A difference exists between CML patients in chronic phase, in which responses to STI571are durable, and patients in blast crisis, who generally experience only transient responses. Leukaemic cells from six CML patients from whom samples could be obtained during chronic phase and at the time of blast crisis (BC) were compared for sensitivity to STI571, using an in vitro assay. BC samples showed a sensitivity similar to that obtained during chronic phase, suggesting that no substantial intrinsic resistance to STI571 was present in BC.